Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis
J Dermatol. 2024;51:1559–1571 doi: 10.1111/1346-8138.17448
Tsai et al. conducted a systematic literature review and network meta-analysis evaluating deucravacitinib and other systemic treatments for moderate-to-severe plaque psoriasis in Asian populations. The authors reported that deucravacitinib achieved PASI75 and PASI90 response rates of 66% and 40%, respectively, higher than placebo and apremilast.
This study utilised 20 randomised controlled trials to indirectly compare the relative effectiveness of systemic therapies in Asian patients with plaque psoriasis, highlighting deucravacitinib’s efficacy. It aimed to assess the differences in systemic treatment outcomes between Asian and White populations, accounting for lifestyle and demographic variations.